The Present and FutureJACC Review Topic of the WeekOral Anticoagulation in Patients With Liver Disease
JACC Review Topic of the Week
Under an Elsevier user license
open archive
Central Illustration
Key Words
anticoagulation
atrial fibrillation
bleeding
liver disease
thrombosis
venous thromboembolism
Abbreviations and Acronyms
AF
atrial fibrillation
EMA
European Medicines Agency
FDA
Food and Drug Administration
INR
international normalized ratio
NAFLD
nonalcoholic fatty liver disease
NOAC
non–vitamin K–antagonist oral anticoagulant agent
OAC
oral anticoagulant agent
PCC
prothrombin complex concentrate
PT
prothrombin time
PVT
portal vein thrombosis
VTE
venous thromboembolism
Cited by (0)
Drs. Qamar and Vaduganathan are supported by the National Heart, Lung, and Blood Institute T32 post-doctoral training grant (T32HL007604). Dr. Greenberger has served on the hepatic clinical endpoint committee of the ENGAGE AF-TIMI 48 trial funded by Daiichi-Sankyo. Dr. Giugliano’s institution has received research grants from Daiichi-Sankyo to support the ENGAGE AF-TIMI 48 trial; honoraria for continuing medical education programs from Daiichi-Sankyo and the American College of Cardiology; and is a compensated consultant for Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Merck, Portola, and Pfizer.
© 2018 by the American College of Cardiology Foundation. Published by Elsevier.